Proof of Concept Module
The goal is to assess the influence of the microbiome on a specific disease. We produce donor-derived, anaerobic, highly viable microbiota products and use them in proof-of-concept indications.
The Next-Generation Microbiome Therapeutics Company
The Microbiome 3.0 Era Has Arrived.
Human Biome's (HBI) mission is to revolutionize global healthcare by developing fully biosynthetic, donor-independent microbiome-based therapeutics that flawlessly mimic and elevate the natural human ecosystem (bio-mimics). To realize this vision, we are pioneering a cutting-edge, deep-tech platform at the intersection of clinical biology, artificial intelligence, and high-throughput automation. Encompassing expertly engineered clinical modules, proprietary AI algorithms, and state-of-the-art high-throughput robotic laboratories, our platform computes, designs, and synthesizes "Super-Microbiome" biotherapeutics—outperforming the highest functional potential ever observed in native human microbiome. This means that „Microbiome 3.0” era has arrived.
Discover Our VisionTechnology
Human Biome stands in an exclusive tier within the global biotech landscape. We possess an end-to-end, proprietary infrastructure capable of clinically validating microbiome-disease linkages in humans, quantifying those links, and ultimately computing, engineering, and synthesizing the "ideal" artificial microbiome drug based on our massive biobank. Collectively named the MicroDrug™ Platform, this ecosystem eliminates the traditional trade-off between clinical efficacy and industrial scalability. We rely on advanced mathematical models, spatial AI algorithms, and deep-tech culturomics to recreate the monumental molecular architecture of the gut microbiota.
Discover Our Technology
Pipeline
New-Generation Biotherapeutics (NGBs) are Human Biome's framework for a new class of microbiome medicines – „bio-mimics". These are donor-independent, biosynthetic therapeutics designed to restore ecosystem-level microbiome function and deliver indication-specific biological activity. The concept is based on a simple but powerful assumption: effective microbiome therapy is not only about which microorganisms are present, but about how they function together, how they interact with the host, and how they are administered over time. In that sense, an NGB is designed as a programmable microbiome medicine rather than a simple microbial mixture.
Explore Our PipelineLatest News
and Press Release
Prof. Jarosław Biliński Delivers Visionary Keynote on Microbiome and Longevity at Impact’26
Human Biome S.A. Explores U.S. Market Expansion at the 2026 SelectUSA Investment Summit
Human Biome S.A. has been awarded financial support within the European Funds for Smart Economy program
Prof. Jarosław Biliński Discusses Longevity and Economic Resilience at the “Go to the Future” Conference
Human Biome S.A. CEO interviewed by Polish Press Agency (PAP)
Patient & Donors
Currently, in the module 1, we produce high-viability, high-cellularity, fully anaerobic fecal microbiota transplant products - capsules and solution. Discover what are the indications for the use of FMT - if you are a patient or physician and would like to order the donor-derived microbiota products. If you want to become a microbiota donor explore what are the rules.
See More